ArticleChronic respiratory disease
Testosterone replacement therapy and hospitalization rates in men with COPD.
Article in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Sexually dimorphic response to tobacco exposure in COPD: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Research frontiers and emerging trends in sex and gender differences in chronic obstructive pulmonary disease: a bibliometric analysis.Journal of thoracic disease · 2026Article
- Cancer disrupts sex hormone-inflammation relationships: Analysis of ALI in males from NHANES 2007-2018.PloS one · 2025Article
- Progesterone (P4) ameliorates cigarette smoke-induced chronic obstructive pulmonary disease (COPD).Molecular medicine (Cambridge, Mass.) · 2024Article
- Testosterone replacement therapy in patients with cachexia: a contemporary review of the literature.Sexual medicine reviews · 2024Review
- Association of serum testosterone with chronic obstructive pulmonary disease (COPD) in a nationally representative sample of White, Black, and Hispanic men.Hormones (Athens, Greece) · 2024Article
- Sex Hormones and Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study and Mendelian Randomization Analysis.International journal of chronic obstructive pulmonary disease · 2024Article
- Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA.BMJ open respiratory research · 2023Observational
- Role of nutrition in patients with coexisting chronic obstructive pulmonary disease and sarcopenia.Frontiers in nutrition · 2023Review
- Testosterone deficiency in male organ transplant recipients.International journal of impotence research · 2022Review
- Androgens and COVID-19: exploring the role of testosterone replacement therapy.International journal of impotence research · 2022Review
- Association of testosterone therapy with disease progression in older males with COVID-19.Andrology · 2022Article
- Association of Male Hypogonadism With Risk of Hospitalization for COVID-19.JAMA network open · 2022Article
- Case Report: Resolution of radiation pneumonitis with androgens and growth hormone.Frontiers in oncology · 2022Article
- Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing.Ageing research reviews · 2022Review
- Testosterone attenuates pulmonary epithelial inflammation in male rats of COPD model through preventing NRF1-derived NF-κB signaling.Journal of molecular cell biology · 2021Article
- Testosterone's Role in COVID-19.The journal of sexual medicine · 2021Article
- Sex- or Gender-specific Differences in the Clinical Presentation, Outcome, and Treatment of SARS-CoV-2.Clinical therapeutics · 2021Review
- Sex-Steroid Signaling in Lung Diseases and Inflammation.Advances in experimental medicine and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Testosterone deficiency is common in men with chronic obstructive pulmonary disease (COPD) and may exacerbate their condition. Research suggests that testosterone replacement therapy (TRT) may have a beneficial effect on respiratory outcomes in men with COPD. To date, however, no large-scale nationally representative studies have examined this association. The objective of the study was to assess whether TRT reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD. We conducted two retrospective cohort studies. First, using the Clinformatics Data Mart-a database of one of the largest commercially insured populations in the United States-we examined 450 men, aged 40-63 years, with COPD who initiated TRT between 2005 and 2014. Second, using the national 5% Medicare database, we examined 253 men, aged ≥66 years, with COPD who initiated TRT between 2008 and 2013. We used difference-in-differences (DID) statistical modeling to compare pre- versus post-respiratory hospitalization rates in TRT users versus matched TRT nonusers over a parallel time period. DID analyses showed that TRT users had a greater relative decrease in respiratory hospitalizations compared with nonusers. Specifically, middle-aged TRT users had a 4.2% greater decrease in respiratory hospitalizations compared with nonusers (-2.4 decrease vs. 1.8 increase; p = 0.03); and older TRT users had a 9.1% greater decrease in respiratory hospitalizations compared with nonusers (-0.8 decrease vs. 8.3 increase; p = 0.04). These findings suggest that TRT may slow disease progression in patients with COPD. Future studies should examine this association in larger cohorts of patients, with particular attention to specific biological pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.